Reinsurance Counterparty Collateral Shortfall Ahead of a Product Launch

Yes, but the framing matters more than the label.

The 45% collateral coverage is a breach of an internal policy limit, not of the solvency risk appetite. These are different instruments: the appetite statement sets the tolerance for loss, the policy sets the operational control that keeps exposure inside tolerance. The CRO should say plainly that a policy breach has occurred, that it is reportable under the firm's own risk event process, and that the cause (an unapplied haircut) is a control failure, not a market event. That distinction prevents the Committee from treating it as bad luck.

The forward-looking question is the real one. Cession rising by 15 percentage points on a guaranteed annuity book pushes counterparty concentration beyond whatever single-name limit sits in the appetite statement. So there is a prospective appetite breach even if today's numbers pass. The CRO should quantify it: post-launch exposure to Aster Re, the loss given a downgrade to BBB, and the replacement cost of the treaty if Aster Re could not be used.

Frame three separable decisions rather than one:

1. Do we allow the launch on the current treaty terms? Options: proceed with conditions, proceed with a cession cap, delay, or place a facultative slice with a second reinsurer.
2. What is the remediation path on Aster Re? Additional collateral, parent guarantee, trust asset eligibility tightening, or partial novation.
3. What tolerance do we have for a rating downgrade during the launch window? A pre-agreed trigger avoids an emergency decision later.

The CRO should resist the CFO's binary. The relationship argument is legitimate but it is a commercial consideration to be weighed against a quantified exposure, not a reason to leave the breach unresolved. A defensible recommendation is conditional approval with a cession cap until coverage reaches 100%, a mandatory downgrade trigger, and a named owner with a dated plan.

The exposure being collateralised is the wrong measure if it is taken as reserves ceded. The economic exposure on reinsurer default is the cost of replacing the cover, plus any unearned premium and any losses already incurred but not yet recovered. Replacement cost rises precisely when the reinsurer is in trouble, because the market hardens and capacity withdraws. The analysis should model exposure at the 99.5th percentile of replacement cost, not the balance sheet ceded reserve.

Collateral quality and legal robustness.

• The haircut that caused the shortfall must be re-derived, not accepted. Check the trust's eligible-asset schedule against the actual holdings, and check duration: long-dated bonds fall in value in a yield spike exactly when the reinsurer's own capital is under strain.
• Is the trust bankruptcy-remote and enforceable in the reinsurer's jurisdiction? Is there set-off risk if the firm also owes premium or profit commission?
• Who controls release of collateral, and on what trigger?

Wrong-way risk. Does the trust hold assets correlated with the firm's own liabilities or with Aster Re's parent? If the trust holds the bonds of a related entity, coverage falls as the risk rises.

Downgrade stress. Model an A− to BBB migration over 12 months: the collateral top-up demand, whether Aster Re can meet it, and the liquidity call on the firm. Then model a two-notch move during the launch, when the firm is least able to renegotiate.

Recovery assumptions. Do not assume 100% recovery even with a trust; assume a delay and legal cost, and test a partial recovery if the trust proves to hold ineligible assets on close-out.

Commercial counterfactual. What does the new product earn if cession is capped at current levels or if a second reinsurer takes 20% at a higher rate? The Committee needs the cost of the mitigation, not only the risk of the status quo.

Recommendation: proceed with the launch on a restricted basis, with named conditions, and report the policy breach formally. Do not treat the CFO's relationship concern as decisive, but do not ignore it - a forced renegotiation three weeks before launch gives the firm no leverage, and the reinsurer knows it.

Conditions.

1. Cession cap. New business cedes no more than the current percentage until trust coverage reaches 100% of the policy requirement under correctly applied haircuts. Any excess goes to a second reinsurer or is retained.
2. Collateral cure within 60 days. Aster Re tops up with eligible assets or provides a parent guarantee. A cure schedule with a hard date, not a target.
3. Downgrade trigger. A move to BBB+ or below automatically suspends new cession, pre-agreed with the Committee so that the decision is taken now rather than in a crisis.
4. Liquidity reserve. Hold a committed buffer equal to the modelled collateral top-up under a two-notch downgrade, so the firm can fund a call without asset fire sales.
5. Concentration limit restated. Amend the appetite statement to express the single-name limit in replacement-cost terms, and report against it monthly until the position normalises.
6. Control remediation. Fix the haircut application, and add a reconciliation between the trust's stated and eligible assets to the monthly risk pack.

What would make me withdraw it: evidence that the trust is not enforceable on close-out; discovery that the shortfall is larger than reported or that other treaties share the same control failure; a downgrade during the window; or a cure schedule that Aster Re will not sign. Any of these converts a manageable concentration into an unsecured credit exposure, and the launch economics do not justify that.